All In Biotech

Drug Trial Radar · NCT07453862

Novel Calcium Channel Modulators in RLS and Variants: Efficacy & Safety

Observation of Efficacy and Safety of Novel Calcium Channel Modulators in the Treatment of Restless Legs Syndrome and Its Variant Subtypes

Last checked: Nov 20, 2026Latest source record: Mar 6, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

20

Planned (sponsor's estimate)

Start

Mar 10, 2026

Primary completion

Jun 30, 2027

Study completion Aug 31, 2027

Sponsor

Lead sponsor
Beijing Friendship HospitalAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Mar 6, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The goal of this \[study type: clinical trial\] is to \[primary purpose: evaluate the efficacy and safety of a novel calcium channel modulator in treating Restless Legs Syndrome (RLS) and its variant subtypes\] in \[describe participant population/primary condition: adult patients aged 18-75 years with confirmed RLS or its variant subtypes, who meet the study's eligibility criteria\]. The main question\[s\] it aims to answer \[is/are\]: * Does the novel calcium channel modulator improve RLS-related symptoms (assessed by the International Restless Legs Syndrome Study Group Rating Scale, IRLS) after the treatment period? * What is the safety profile (incidence of adverse events) of this calcium channel modulator in RLS patients? Participants will \[describe the main tasks participants will be asked to do, interventions they'll be given\]: * Receive oral administration of the novel calcium channel modulator (40mg twice daily) for 12 consecutive weeks * Complete scheduled follow-up visits for symptom assessments, safety monitoring, and questionnaire completion

Conditions

  • Restless Leg Syndrome (RLS)
  • Variant Restless Legs Syndrome

Interventions

  • CrisugabalinDrug

    Participants will receive oral administration of Crisugabalin for 12 consecutive weeks. No other drugs affecting RLS symptoms will be allowed during the study. Clinical assessments and safety monitoring will be conducted at scheduled follow-up visits.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change in International Restless Legs Syndrome Scale (IRLS) Score from Baseline to Week 12Time frame: Baseline (pre-treatment) and Week 12 (end of treatment)
  2. Change in International Restless Legs Syndrome Scale (IRLS) Score from Baseline to Week 12Time frame: Baseline (pre-treatment) and Week 12 (end of treatment)

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Capital Medical University Affiliated Beijing Friendship Hospital

    Beijing, Beijing Municipality, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.